GMP quality systems
A pharmaceutical quality system (PQS) is the management system that makes GMP work as a whole rather than as a set of separate procedures — defined by EU GMP Chapter 1 and elaborated by ICH Q10.
A pharmaceutical quality system (PQS) is the management system that makes GMP work as a whole rather than as a set of separate procedures — defined by EU GMP Chapter 1 and elaborated by ICH Q10.
Plain-English explanation, then the primary regulation it comes from.
Understanding gmp quality systems
Chapter 1 of EU GMP requires a pharmaceutical quality system, and ICH Q10 describes what a good one contains across the product lifecycle. The important word is system: the point is that deviations, CAPA, change control, risk management and management review connect to each other. A site can have excellent individual procedures and still have no quality system, because nothing joins them up.
ICH Q10 adds four elements that sit above the day-to-day processes: a process performance and product quality monitoring system, a CAPA system, a change management system, and management review. Those four are the loop. Monitoring detects, CAPA corrects, change management implements, and management review decides what gets resourced. Break any one and the other three degrade.
Most quality systems are not badly designed. They are designed for a larger organisation than the one running them. A workflow assuming a dedicated document controller, a standing review board and three approval levels works beautifully where those exist and quietly breaks where one person is all three. The result is informal workarounds, then drift between the written procedure and the real process — which is precisely what an inspector is trained to find.
The usable test is simple: could a competent new QA officer follow this system in their first month without asking a colleague? Where the answer is no, the reason is usually structural rather than a matter of wording.
- Product realisation
- The system delivers products with the quality attributes patients and the marketing authorisation require.
- State of control
- Process performance and product quality are monitored so that the system's actual capability is known, not assumed.
- Continual improvement
- CAPA and change management drive improvement, informed by risk and by data rather than by opinion.
- Management responsibility
- Senior management owns the system, sets quality objectives, provides resources and reviews effectiveness at defined intervals.
- Knowledge and risk management
- The two enablers running through ICH Q10: product and process knowledge, and quality risk management as the basis for decisions.
Common failure modes
- A quality manual describing an organisation the site does not have, so the written system and the real one diverge from day one.
- Management review as a reporting meeting, producing minutes rather than funded decisions with owners and dates.
- Quality metrics collected because a procedure requires it, with nobody interpreting the trend they show.
- Over-engineered approval routes that push the business into working around quality rather than through it.
Where this is written down
- European CommissionEudraLex Volume 4 — EU GMP guidelines
Part I, Chapter 1 — Pharmaceutical Quality System
- ICHICH Quality guidelines (Q1–Q14)
ICH Q10 — Pharmaceutical Quality System
Read next
Quality management system (QMS)
ReadQualityCAPA
ReadQualityChange control
ReadQualityQuality risk management (QRM)
ReadLooking for a definition rather than an explanation? The GMP glossary covers the abbreviations in one line each.
Knowing the requirement is not the same as closing the gap
If you want to know where your site actually stands against this, the readiness score covers seven quality-system domains in twenty questions, and takes about ten minutes.